Tuesday, November 9, 2021

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Honeywell International Inc. (HON), and Zoetis Inc. (ZTS). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Walmart have lagged the broader marekt this year (up +3.5% in the year-to-date period vs. +26.5% gain for the S&P 500 index) as the market sees the company vulnerable to ongoing supply-chain issues. The Zacks analyst has favorable outlook for the company and sees the company continuing to gain ground on the back of its omnichannel efforts.

In order to boost e-commerce sales, the company is strengthening its delivery capabilities. This, along with efforts to enhance store experience, fueled second-quarter results. Walmart also raised its fiscal 2022 guidance on the back of robust underlying market trends. The company, however, has been encountering high costs related to the ongoing pandemic, as well as increased wage expense.

(You can read the full research report on Walmart here >>>)

Honeywell shares have gained +7.5% in the year to date period against the Zacks Diversified Operations industry’s gain of +15.8%. It has been dealing with high costs as well as supply chain challenges, which might stress its margins. Weakness in the defense and space businesses are likely to adversely impact its near-term results.

The Zacks analyst, however, believes that the company is poised to benefit from strength in warehouse and workflow solutions business, along with recovery in the commercial aviation business in the quarters ahead. Operational excellence initiatives, acquisitions, and strong cash flow are likely to further drive Honeywell's competency.

(You can read the full research report on Honeywell here >>>)

Shares of Zoetis have gained +34.8% over the past year against the Zacks Drugs industry’s loss of -14.3%. The Zacks analyst believes that a diversified product portfolio, global footprint and productive R&D should keep driving both top-and bottom-line growth.

Its third quarter results were driven by strong performances from its portfolio of petcare parasiticides, including Simparica Trio, as well as dermatology products. The uptake of Librela and Solensia, its new monoclonal antibody therapies for osteoarthritis pain in dogs and cats is another major positive. Development and regulatory setbacks for late-stage pipeline candidates and stiff competition in the animal health space remain major threats to the company though.

(You can read the full research report on Zoetis here >>>)

Other noteworthy reports we are featuring today include Air Products and Chemicals, Inc. (APD), Colgate-Palmolive Company (CL) and IDEXX Laboratories, Inc. (IDXX).

Sheraz Mian

Director of Research

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>